Brenner, I. R., Flanagan, C. F., Penazzato, M., Webb, K. A., Horsfall, S. B., Hyle, E. P., Abrams, E., Bacha, J., Neilan, A. M., Collins, I. J., Desmonde, S., Crichton, S., Davies, M.-A., Freedberg, K. A., & Ciaranello, A. L. (2024). Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis. The Lancet Global Health, 12(12), e2068–e2079. https://doi.org/10.1016/s2214-109x(24)00381-4

Jhaveri, K. L., Accordino, M. K., Bedard, P. L., Cervantes, A., Gambardella, V., Hamilton, E., Italiano, A., Kalinsky, K., Krop, I. E., Oliveira, M., Schmid, P., Saura, C., Turner, N. C., Varga, A., Cheeti, S., Hilz, S., Hutchinson, K. E., Jin, Y., Royer-Joo, S., … Juric, D. (2024). Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 42(33), 3947–3956. https://doi.org/10.1200/jco.24.00110

Abrams, E. J., Jao, J., Madlala, H. P., Zerbe, A., Catalano, P., Gerschenson, M., Goedecke, J. H., Gomba, Y., Josefson, J., Kurland, I. J., Legbedze, J., McComsey, G. A., Matyesini, S., Mukonda, E., Robinson, D., & Myer, L. (2024). An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol. PLOS ONE, 19(8), e0307296. https://doi.org/10.1371/journal.pone.0307296

Fojo, T., LaRose, M., & Bates, S. E. (2024). The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype. The Oncologist, 29(4), 275–277. https://doi.org/10.1093/oncolo/oyae042

Mok, S., & Fidock, D. A. (2024). Determinants of piperaquine-resistant malaria in South America. The Lancet Infectious Diseases, 24(2), 114–116. https://doi.org/10.1016/s1473-3099(23)00564-9

Hagenah, L. M., Dhingra, S. K., Small-Saunders, J. L., Qahash, T., Willems, A., Schindler, K. A., Rangel, G. W., Gil-Iturbe, E., Kim, J., Akhundova, E., Yeo, T., Okombo, J., Mancia, F., Quick, M., Roepe, P. D., Llinás, M., & Fidock, D. A. (2024). Additional PfCRT mutations driven by selective pressure for improved fitness can result in the loss of piperaquine resistance and altered Plasmodium falciparum physiology. MBio, 15(1). https://doi.org/10.1128/mbio.01832-23

Ayaz, P., Lyczek, A., Paung, Y., Mingione, V. R., Iacob, R. E., de Waal, P. W., Engen, J. R., Seeliger, M. A., Shan, Y., & Shaw, D. E. (2023). Structural mechanism of a drug-binding process involving a large conformational change of the protein target. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36956-5

Langelier, M.-F., Lin, X., Zha, S., & Pascal, J. M. (2023). Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Science Advances, 9(12). https://doi.org/10.1126/sciadv.adf7175

Small-Saunders, J. L., Hagenah, L. M., Wicht, K. J., Dhingra, S. K., Deni, I., Kim, J., Vendome, J., Gil-Iturbe, E., Roepe, P. D., Mehta, M., Mancia, F., Quick, M., Eppstein, M. J., & Fidock, D. A. (2022). Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance. PLOS Pathogens, 18(2), e1010278. https://doi.org/10.1371/journal.ppat.1010278

Kantrowitz, J. T. (2021). Additional perspective on cariprazine and negative symptoms. Expert Opinion on Pharmacotherapy, 23(12), 1469–1470. https://doi.org/10.1080/14656566.2021.1968828